Modified Robust Meta-Analytic-Predictive Priors for Incorporating Historical Controls in Clinical Trials

References

• Box, G. E. P. (1980), “Sampling and Bayes Inference in Scientific Modeling and Robustness,” Journal of the Royal Statistical Society, Series A, 143, 383–430. DOI: 10.2307/2982063.
   Web of Science ®Google Scholar
• Center for Devices and Radiological Health (CDRH). (2021), “Examples of Real-World Evidence (RWE) Used in Medical Device Regulatory Decisions,”available at https://www.fda.gov/media/146258/download.
   Google Scholar
• Duan, Y., Ye, K., and Smith, E. P. (2006), “Evaluating Water Quality Using Power Priors to Incorporate Historical Information,” Environmetrics, 17, 95–106. DOI: 10.1002/env.752.
   Web of Science ®Google Scholar
• European Medicines Agency (EMA). (2021), “Guideline on Registry-based Studies,” available at https://www.ema.europa.eu/en/guideline-registry-based-studies-scientific-guideline.
   Google Scholar
• FDA (2017), “Guidance for Industry and Food and Drug Administration Staff: Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices,” available at https://www.fda.gov/media/99447/download.
   Google Scholar
• FDA (2019a), “Guidance for Industry: Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products,” available at https://www.fda.gov/media/133660/download.
   Google Scholar
• FDA (2019b), “Guidance for Industry: Rare Diseases: Common Issues in Drug Development,” available at https://www.fda.gov/media/120091/download. (Revision 1).
   Google Scholar
• FDA (2019c), “Guidance for Industry: Rare Diseases: Natural History Studies for Drug Development,” available at https://www.fda.gov/media/122425/download.
   Google Scholar
• FDA (2021), “Guidance for Industry: Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products,” available at https://www.fda.gov/media/154714/download.
   Google Scholar
• Gravestock, I., and Held, L, & COMBACTE-Net consortium (2017), “Adaptive Power Priors with Empirical Bayes for Clinical Trials,” Pharmaceutical Statistics, 16, 349–360. DOI: 10.1002/pst.1814.
   PubMed Web of Science ®Google Scholar
• Hobbs, B. P., Carlin, B. P., Mandrekar, S. J., and Sargent, D. J. (2011), “Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials,” Biometrics, 67, 1047–1056. DOI: 10.1111/j.1541-0420.2011.01564.x.
   PubMed Web of Science ®Google Scholar
• Hobbs, B. P., Carlin, B. P., and Sargent, D. J. (2013), “Adaptive Adjustment of the Randomization Ratio Using Historical Control Data,” Clinical Trials (London, England), 10, 430–440. DOI: 10.1177/1740774513483934.
   PubMed Web of Science ®Google Scholar
• Jiang, L., Nie, L., and Yuan, Y. (2023), “Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials,” Biometrics, 79, 49–60. DOI: 10.1111/biom.13551.
   PubMed Web of Science ®Google Scholar
• Neuenschwander, B., Capkun-Niggli, G., Branson, M., and Spiegelhalter, D. J. (2010), “Summarizing Historical Information on Controls in Clinical Trials,” Clinical Trials, 7, 5–18. DOI: 10.1177/1740774509356002.
   PubMed Web of Science ®Google Scholar
• Petrone, S., Rousseau, J., and Scricciolo, C. (2014), “Bayes and Empirical Bayes: Do They Merge?” Biometrika, 101, 285–302. DOI: 10.1093/biomet/ast067.
   Web of Science ®Google Scholar
• Pocock, S. J. (1976), “The Combination of Randomized and Historical Controls in Clinical Trials,” Journal of Chronic Diseases, 29, 175–188. DOI: 10.1016/0021-9681(76)90044-8.
   PubMedGoogle Scholar
• Rubinstein, E., Cammarata, S. K., Oliphant, T. H., and Wunderink, R. G. (2001), “Linezolid versus Vancomycin in the Treatment of Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study,” Clinical Infectious Diseases, 32, 402–412. DOI: 10.1086/318486.
   PubMed Web of Science ®Google Scholar
• Schmidli, H., Gsteiger, S., Roychoudhury, S., O’Hagan, A., Spiegelhalter, D., and Neuenschwander, B. (2014), “Robust Meta-Analytic-Predictive Priors in Clinical Trials with Historical Control Information,” Biometrics, 70, 1023–1032. DOI: 10.1111/biom.12242.
   PubMed Web of Science ®Google Scholar
• Viele, K., Berry, S., Neuenschwander, B., Amzal, B., Chen, F., Enas, N., Hobbs, B., Ibrahim, J. G., Kinnersley, N., Lindborg, S., Micallef, S., Roychoudhury, S., and Thompson, L. (2014), “Use of Historical Control Data for Assessing Treatment Effects in Clinical Trials,” Pharmaceutical Statistics, 13, 41–54. DOI: 10.1002/pst.1589.
   PubMed Web of Science ®Google Scholar
• Wunderink, R. G., Cammarata, S. K., Oliphant, T. H., and Kollef, M. H, & Linezolid Nosocomial Pneumonia Study Group. (2003), “Continuation of a Randomized, Double-Blind, Multicenter Study of Linezolid versus Vancomycin in the Treatment of Patients with Nosocomial Pneumonia,” Clinical Therapeutics, 25, 980–992. DOI: 10.1016/s0149-2918(03)80118-2.
   PubMed Web of Science ®Google Scholar